Indacaterol vs Tiotropium: Tie on FEV1; Spiriva wins on exacerbations
www.pulmccm.org
Once-daily long-acting beta agonist indacaterol (Arcapta Neohaler) went head to head against tiotropium (Spiriva) in a randomized trial among 3,444 patients with severe COPD, funded by indacaterol makers Novartis. Indacaterol, approved in 2011 as a treatment for COPD, was deemed noninferior to tiotropium according to the prespecified criteria of the trial, bronchodilating almost identically (a
Indacaterol vs Tiotropium: Tie on FEV1; Spiriva wins on exacerbations
Indacaterol vs Tiotropium: Tie on FEV1…
Indacaterol vs Tiotropium: Tie on FEV1; Spiriva wins on exacerbations
Once-daily long-acting beta agonist indacaterol (Arcapta Neohaler) went head to head against tiotropium (Spiriva) in a randomized trial among 3,444 patients with severe COPD, funded by indacaterol makers Novartis. Indacaterol, approved in 2011 as a treatment for COPD, was deemed noninferior to tiotropium according to the prespecified criteria of the trial, bronchodilating almost identically (a